Grail, Inc. (NASDAQ:GRAL - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 5,300,000 shares, a decrease of 14.5% from the January 15th total of 6,200,000 shares. Approximately 18.9% of the company's shares are short sold. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is currently 5.2 days.
Grail Trading Up 11.6 %
Shares of NASDAQ:GRAL traded up $5.47 on Wednesday, hitting $52.60. The company had a trading volume of 2,028,174 shares, compared to its average volume of 1,457,021. The firm's 50-day simple moving average is $25.78 and its two-hundred day simple moving average is $18.86. Grail has a 1 year low of $12.33 and a 1 year high of $63.99.
Wall Street Analyst Weigh In
GRAL has been the topic of a number of research analyst reports. Wolfe Research began coverage on Grail in a report on Friday, November 15th. They set a "peer perform" rating on the stock. Morgan Stanley assumed coverage on Grail in a research report on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price objective on the stock.
View Our Latest Report on GRAL
Institutional Trading of Grail
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Douglas Lane & Associates LLC bought a new stake in shares of Grail during the 4th quarter valued at $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new position in Grail in the 4th quarter worth approximately $430,000. FNY Investment Advisers LLC bought a new position in shares of Grail during the fourth quarter valued at $26,000. 180 Wealth Advisors LLC purchased a new stake in shares of Grail during the 4th quarter valued at about $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new stake in Grail in the fourth quarter worth approximately $387,000.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
